

# TAK-901

Catalog No: tcsc0243



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

934541-31-8

**Formula:**

$C_{28}H_{32}N_4O_3S$

**Pathway:**

Cell Cycle/DNA Damage;Epigenetics

**Target:**

Aurora Kinase;Aurora Kinase

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 2 mg/mL (3.96 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

504.64


## Product Description

TAK-901 is a multi-targeted **aurora** inhibitor with **IC<sub>50</sub>**s of 21 and 15 nM for aurora A and B, respectively.

IC50 & Target: IC50: 21 nM (aurora A), 15 nM (aurora B), 1.2 nM (JAK3), 1.3 nM (Src), 2 nM (FGR), 5 nM (FLT3)<sup>[1]</sup>

**In Vitro:** TAK-901 exhibits time-dependent, tight-binding inhibition of Aurora B, but not Aurora A. Consistent with Aurora B inhibition, TAK-901 suppresses cellular histone H3 phosphorylation and induces polyploidy. In various human cancer cell lines, TAK-901 inhibits cell proliferation with effective concentration values from 40 to 500 nM. Examination of a broad panel of kinases in biochemical assays reveals inhibition of multiple kinases. However, TAK-901 potently inhibits only a few kinases other than Aurora B in intact cells, including FLT3 and FGFR2<sup>[1]</sup>.

**In Vivo:** In rodent xenografts, TAK-901 exhibits potent activity against multiple human solid tumor types, and complete regression is observed in the ovarian cancer A2780 model. TAK-901 also displayed potent activity against several leukemia models. TAK-901 induces pharmacodynamic responses consistent with Aurora B inhibition and correlating with retention of TAK-901 in tumor tissue<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!